U.S. Bill Aims To Streamline Combo Product Regulation
This article was originally published in PharmAsia News
Executive Summary
In a move that could affect applicants from Asia and elsewhere, a U.S. Senate bill aims to streamline device/drug combination registrations at the FDA by letting the agency rely on prior premarket approvals and approved drug findings to help support new product approvals, among other reforms.